Nuvo Pharmaceuticals v. Dr. Reddy's Laboratories Inc., No. 17-2473 (Fed. Cir. May 15, 2019)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Dr. Reddy’s Laboratories, Inc., Mylan Pharmaceuti- cals, and Lupin Pharmaceuticals (collectively, “the Gener- ics”) appeal from the final judgment of the United States District Court for the District of New Jersey following a bench trial upholding the asserted claims of U.S. Patent Nos. 6,926,907 (“the ’907 patent”) and 8,557,285 (“the ’285 patent”) as nonobvious under 35 U.S.C. § 103, enabled NUVO PHARMACEUTICALS v. DR. REDDY’S LABORATORIES 3 under 35 U.S.C. § 112, and adequately described under § 112. Nuvo Pharmaceuticals, Inc.